VGF Antibodies

Neurosecretory protein VGF (VGF)

May be involved in the regulation of cell-cell interactions or in synatogenesis during the maturation of the nervous system. .

.

Gene Information

Human
Gene Name:	VGF
Uniprot:	O15240
Entrez:	7425

Family

Belongs to:
No superfamily

Alternative Names

neuro-endocrine specific protein VGF; neurosecretory protein VGF; VGF nerve growth factor inducible; VGF

Molecular Weight

Mass (kDA):
67.258 kDA

Genomic Context

Human
Location:	7q22.1
Sequence:	7; NC_000007.14 (101162509..101169956, complement)

Tissue Specificity

Central and peripheral nervous systems, synthesized exclusively in neuronal and neuroendocrine cells.

Subcellular Localizations

[Neurosecretory protein VGF]: Secreted. Cytoplasmic vesicle, secretory vesicle. Stored in secretory vesicles and then secreted, NERP peptides colocalize with vasopressin in the storage granules of hypothalamus.

Diseases

• Vaccinia
• Nervousness
• Pituitary Diseases
• Depressive Disorder
• Disease Of Adrenal Medulla
• Pheochromocytoma
• Neoplasms
• Alzheimer's Disease
• Obesity
• Mental Disorders
• Schizophrenia
• Dementia
• Hyperplasia

• Mood Disorders
• Malignant Neoplasms
• Diabetes Mellitus
• Major Depressive Disorder
• Virus Diseases
• Adrenal Gland Neoplasms
• Sclerosis

Pathways

• Secretion
• Energy Homeostasis
• Pathogenesis
• Secretory Pathway
• Cell Growth
• Neurogenesis
• Virulence
• Localization
• Viral Replication
• Transport
• Synaptic Transmission
• Glucose Homeostasis
• Cell Differentiation

• Regulated Secretory Pathway
• Proteolysis
• Protein Secretion
• Cell Cycle
• Methylation
• Cell Death
• Swimming

PTMs

• Cleavage
• Phosphorylation
• Amidation

• Methylation
• Glycosylation
• Carboxylation

• Oxidation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/VGF

Best Uses Of The VGF Marker

The extracellular domain of the TNF receptor 2 (TNFR2) was reengineered through fusion with the VEGF dimerization domain and a BBB-penetrating peptide. The result was the boster-bio: VGF receptor 2, (Bo). Boster bio provides a wide variety secondary antibodies, isotype checks, and detection methods optimized for IHC. Here are some frequently asked questions about the Boster Bio:

TNF receptor2 extracellular domain, (TNFR2), was reengineered with its fusion as a BBB penetration peptide(MTH) and VEGF dimerization.

TNF-a has been shown to reduce eNOS expression and KDR/Flk-1 levels in ECs. Transfection of siRNA into human urochete cells (HUVECs) increased expression of these factors. Transfections with siRNA into HUVECs led to significant increases in expression of angiogenic genes and anti-apoptotic Bax. Transfection of siRNA into HUVECs significantly lowered the HUVEC apoptotic rate, enhanced proliferation, and capillary formation.

The extracellular TNF-receptor 2 (TNFR2)'s domain was reengineered with fusion to a BBB permeabilizing peptide and VEGF dimerization. This new TNF 2 form is capable of binding both VEGF & BBB and inhibits its cytotoxic properties.

TNF receptor 2, a tumor necrosis factors-induced cytokine, restores oxygen to tissues when they are under hypoxic conditions. It is also found at high levels in patients suffering from bronchial or diabetes mellitus. It promotes the formation of new blood vessels after exercise and trauma. Apart from its positive role in human health, VEGF can also be implicated in several diseases. Overexpression of the receptor may lead to vascular problems in the retina, and other parts.

TNF receptors can be used as therapeutic targets in myocardial Ischemia and hindlimb Ischemia. Further research is needed in order to determine if fusions TNFR-2 and a BBB piercing peptide can prevent VEGF from binding to ECs.

In vitro experiments were conducted in which TNF receptor 2, a BBB peptide, and the adipogenic VeGF dimerization Domain fused with each other. The anti-inflammatory effect was confirmed. These findings support the role of BDNF in the autonomic regulation of homoostasis.

These studies have shown that the CRF1 receptor and I+2-adrenergic receptors may play an important role in the regulation of the endocannabinoid system. These findings also suggest that CRF may play a role during the heroin withdrawal-potent beginle in rats.

Best uses for VEGF-marker

VEGF, a potent angiogenic molecule, plays an important role within cardiovascular biology. Its potential therapeutic applications in vivo and in vitro are well established. Recent reviews of VEGF biology highlight its important role in a range of different diseases. This review will examine how this marker is used for clinical research. Let's also consider the future of VEGFs for cardiovascular medicine.

VEGF is a proteolytically processed protein that can be broken down into two forms, VEGF–C and VEGF–D. Both proteins bind to VEGFR-2. Molecular names of VEGF include DAG (diacylglycerol), eNOS [endothelial nitric oxygen synthase], EPC (endothelial precell), IP3 (inositol phosphate), NO, and EPC (endothelial precursor cells). These molecules are present in the human body, but they are not essential for human health.

We investigated the effects VEGF164 had on lung tissue by using a confocal microscopy and Zeiss ZEN Blue Image Analysis Software. The VEGF-164 treatment significantly increased pulmonary tissue proliferation. ERG and Ki-67 co-staining showed that it increased the proliferation of nuclear endothelial cells. The VEGF-164 treatment also resulted in a significant increase global lung cell proliferation.

VEGFD treatment promotes tumor cell growth in mouse models. The percentage of sentinel lymph nodes containing this marker in mice with VEGF-D xenografts was 69.2% in mice, whereas it was 16.7% for mice with SKOV3 xenografts. In both treatments, the percentage tumor cells with CA125 was 0.01 percent or less.